Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio
M & A Critique|April 2024
Recently, Eris Lifesciences Limited announced acquisition of 'branded Formulation Business' of Biocon Biologics Limited pertaining to the India territory through slump sale. In addition, ELL also announced a foreign acquisition.
Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio

Eris Lifesciences Limited ("ELL" or "Eris") is a publicly listed Indian pharma company and is a leading player in the domestic branded formulations market. Established in 2007, ELL has been focusing on chronic and sub chronic lifestyle related therapies. ELL is fully integrated business with manufacturing facilities in Guwahati and Gujarat.

As part of its adding strategic growth engines strategy, ELL entered the Indian insulin market in 2022 with joint venture (70% with ELL) with MJ Biopharm. The JV commenced two products and INR 18 crore revenue in first year of operations and currently having monthly run rate of circa INR 5 crore. To achieve annual revenues of INR 1000 crore in near future from Diabetes care portfolio, ELL announced two major back-to-back acquisitions which shall facilitate exports & domestic growth.

Eris has historically leveraged acquisitions to enter new therapies; it entered Neuropsychiatry in 2017 through the acquisition of Strides Shasun's domestic business and entered Dermatology in 2022 through the acquisition of Oaknet Healthcare, followed by brand portfolios from Glenmark and Dr. Reddy's in early 2023.

In November 2023, Eris & Biocon Biologics Limited announced strategic partnership to evaluate ways to strengthen Nephrology and Dermatology business owned by Biocon Biologics using strong footholds of Eris in particular area. As a part of this, ELL acquired Biocon Biologics Branded Formulations' India (BFI) business units of Nephrology and Dermatology on a slump sale basis.

The business includes over 20 mother brands with FY23 Revenue of INR 90 cr and current revenue run-rate of INR 100 cr. The deal consideration is INR 366 crore inclusive of working capital conveyed as part of the deal.

Post deal Eris will become the 2nd largest player in Psoriasis with a market share of 11%. The transaction was partly funded through debt & internal accruals.

This story is from the April 2024 edition of M & A Critique.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the April 2024 edition of M & A Critique.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM M & A CRITIQUEView All
Batliboi Ltd. merging its associate company
M & A Critique

Batliboi Ltd. merging its associate company

Batliboi Limited has a history of collaborations with various foreign technical partners and has subsidiaries like Hydraulic & General Engineers Ltd. and Batliboi International Ltd. In March 2024, the board of Directors of Batliboi Limited accorded their approval for the merger of promoter owned private company with itself.

time-read
2 mins  |
May 2024
TVS Motors issuances of convertible preference shares as bonus instead of dividend
M & A Critique

TVS Motors issuances of convertible preference shares as bonus instead of dividend

Recently, well known auto manufacturer announced the issuance of preference shares as a bonus to all equity shareholders.

time-read
3 mins  |
May 2024
Aditya Birla Fashion & Retails Scheme to undo its consolidation
M & A Critique

Aditya Birla Fashion & Retails Scheme to undo its consolidation

Corporate restructuring saga continues for Aditya Birla Group.

time-read
5 mins  |
May 2024
Advent International to combine its listed & private entity business
M & A Critique

Advent International to combine its listed & private entity business

Recently, Advent International announced the merger of its privately held pharma company into recently acquired listed pharma company.

time-read
6 mins  |
April 2024
Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio
M & A Critique

Eris Lifesciences on Acquisition Spree to expand its branded formulations portfolio

Recently, Eris Lifesciences Limited announced acquisition of 'branded Formulation Business' of Biocon Biologics Limited pertaining to the India territory through slump sale. In addition, ELL also announced a foreign acquisition.

time-read
7 mins  |
April 2024
Vuenow Merges All Entities Will It Create Value?
M & A Critique

Vuenow Merges All Entities Will It Create Value?

Recently, Vuenow Infratech Limited, a BSE listed company, announced the merger of two private companies itself.

time-read
6 mins  |
April 2024
Dalmia Group continues its journey of segregation of businesses by way of demerger
M & A Critique

Dalmia Group continues its journey of segregation of businesses by way of demerger

Recently Dalmia Group announced yet another restructuring of one of its group companies Dalmia Bharat Refractories Limited.

time-read
6 mins  |
March 2024
Rane Group to consolidate its listed operational entities
M & A Critique

Rane Group to consolidate its listed operational entities

After keeping different operational listed entities for years, Rane Group, one of the key players in Auto Ancillary space has decided to consolidate its listed operational companies under Rane (Madras) Limited.

time-read
3 mins  |
March 2024
Zuari Group's attempts to create the biggest private producer of Fertilisers
M & A Critique

Zuari Group's attempts to create the biggest private producer of Fertilisers

“Transfer of Identified shares from ZACL to ZMPPL is a precondition for approval of the merger transaction”

time-read
7 mins  |
March 2024
Shankara Building Products separates its trading & marketplace business for independent growth
M & A Critique

Shankara Building Products separates its trading & marketplace business for independent growth

Recently, Shankara Building Products Limited announced the demerger of its trading/building material marketplace business from its manufacturing business.

time-read
4 mins  |
February 2024